Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer.

Current pharmaceutical design - 1 Jan 2021

Moradi-Marjaneh Reyhaneh, Asgharzadeh Fereshteh, Khordad Elnaz, Marjaneh Mahdi Moradi

Abstract excerpt

Colorectal cancer (CRC) is one of the most common leading causes of cancer death in the world. Although EGFR inhibitors have established efficacy in metastatic colorectal cancer (mCRC), some patients do not respond to this treatment. The EGFR inhibitors' failure and acquired resistance are partly due to KRAS and BRAF mutations. Thus, prognostic biomarkers that help to select eligible patients are highly in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Colorectal Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 33030125
DOI: 10.2174/1381612826666201007163116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer.PMID 33030125Read ↗

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.Semantic proximity Read ↗

Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.Semantic proximity Read ↗

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.Semantic proximity Read ↗

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA.Semantic proximity Read ↗

Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.Semantic proximity Read ↗

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.Semantic proximity Read ↗

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancerSemantic proximity Read ↗

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer.Semantic proximity Read ↗

Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.Semantic proximity Read ↗

Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.